Pembrolizumab Monotherapy for the Treatment of High-Risk Non–Muscle Invasive Bladder Cancer Unresponsive to BCG

Read it now on PracticeUpdate.com

Read the full article here

Source: PracticeUpdate
Categories: Hem/Oncs, Latest Headlines
Tags:
Tweets with this article
Guru Sonpavde, MD
Pembro-41% 3-month-CR (n=96) in BCG-unresponsive CIS #bladdercancer+/-papillary tumors-median duration of response 16 mo, no muscle-invasive progression-Grade ≥3 toxicities in 13%-intravesical agents arriving soon?-Adstiladrin, Vicinium https://t.co/U8JKa4HPKL @practiceupdate

Related Articles